Infliximab treatment for pediatric refractory Kawasaki disease

Pediatric Cardiology

Volumn 32, Issue 7, 2011, Pages 1023-1027

  Blaisdell, Laura L ^a   Hayman, Jennifer A ^b   Moran, Adrian M ^a  

^a MAINE MEDICAL CENTER   (United States)

^b Barbara Bush Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATENOLOL; BILIRUBIN; C REACTIVE PROTEIN; ENOXAPARIN; HEMOGLOBIN; HEPARIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; OMEPRAZOLE; SODIUM; WARFARIN; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ARTICLE; CASE REPORT; CHAPPED LIPS; CHILD; CONJUNCTIVITIS; DRUG MEGADOSE; EDEMA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOLLOW UP; GROWTH, DEVELOPMENT AND AGING; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEPARINIZATION; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LOOSE FECES; LOW DRUG DOSE; LYMPHOCYTE; MACULOPAPULAR RASH; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEDIATRIC REFRACTORY KAWASAKI DISEASE; PHYSICAL EXAMINATION; POLYMORPHONUCLEAR CELL; RASH; RECURRENT FEVER; RIGHT CORONARY ARTERY; SACCULAR ANEURYSM; SCHOOL CHILD; SKIN EXAMINATION; TACHYCARDIA; THROMBOCYTE COUNT; URINALYSIS; VOMITING; ANGIOCARDIOGRAPHY; CORONARY ARTERY ANEURYSM; DOSE RESPONSE; DRUG ANTAGONISM; ECHOCARDIOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CORONARY ANEURYSM; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859648458     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-011-0045-2     Document Type: Article

References (34)

1. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW (1998) A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 81:1116-1120
2. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17:1144-1148
3. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD et al (2005) Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146:662-667
4. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 153:833-838
5. Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP (2008) Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics 122:e786-e790
6. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24:145-148
7. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M et al (2006) Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149:237-240
8. Han RK, Silverman ED, Newman A, McCrindle BW (2000) Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 154:694-699
9. Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33:805-810
10. Hashino K, Ishii M, Iemura M, Akagi T, Kato H (2001) Retreatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43:211-217
11. Imagawa T, Mori M, Miyamae T, Ito S, Nakamura T, Yasui K et al (2004) Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 163:263-264
12. Iwashima S, Seguchi M, Matubayashi T, Ohzeki T (2007) Ulinastatin therapy in Kawasaki disease. Clin Drug Invest 27:691-696
13. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y et al (1996) Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 94:1379-1385
14. Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 16:178-222
15. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T et al (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606-2612
16. Kobayashi T, Inoue Y, Tamura K, Morikawa A, Kobayashi T (2007) External validation of a scoring system to predict resistance to intravenous immunoglobulin. J Pediatr 150:e37; author reply e38
17. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2:1298-1302
18. Matsubara T, Furukawa S, Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56:29-36
19. Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K et al (2004) Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 89:776-780
20. Momenah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW (1998) Kawasaki disease in the older child. Pediatrics 102:e7
21. Muta H, Ishii M, Sakaue T, Egami K, Furui J, Sugahara Y et al (2004) Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 114:751-754
22. Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95:189-193
23. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL et al (2007) Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 356:663-675
24. O'Connor MJ, Saulsbury FT (2007) Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr Phila 46:345-348
25. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A et al (2007) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4
26. Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A et al (2008) Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J 72:850-852
27. Raman V, Kim J, Sharkey A, Chatila T (2001) Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 20:635-637
28. Saji T (2008) Clinical utility of ulinastatin, urinary protease inhibitor in acute Kawasaki disease. Nippon Rinsho 66:343-348
29. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M et al (2008) Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 27:155-160
30. Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105:E78
31. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808-810
32. Williams RV, Wilke VM, Tani LY, Minich LL (2002) Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109:E4
33. Wright DA, Newburger JW, Baker A, Sundel RP (1996) Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 128:146-149
34. Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O (2006) Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol 24:453